Strategies for cancer gene therapy using adenoviral vectors

Journal of Molecular Medicine

Volumn 74, Issue 4, 1996, Pages 183-189

  Descamps, V ^a   Duffour, M T ^a   Mathieu, M C ^a   Fernandez, N ^a   Cordier, L ^a   Abina, M A ^a   Kremer, E ^a   Perricaudet, M ^a   Haddada, H ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Adenoviral vector; Cancer; Gene therapy; Immunotherapy

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; INTERLEUKIN 2; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; IMMUNOTHERAPY; IN VITRO STUDY; NONHUMAN; REVIEW; TECHNIQUE; TUMOR CELL;

EID: 0029943820     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00204748     Document Type: Review

References (69)

1. Aoki T, Tashiro K, Miyatake S, Kinash T, Nakano T, Oda Y, Kikuchi H, Honjo T (1992) Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 89:3850-3854
2. Asher AL, Mulé JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, Jaffe G, Fendly B, Kriegler M, Rosenberg SA (1991) Murine tumor cells transduced with the gene for tumor necrosis factor-alpha: evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 146:3227-3234
3. Barba D, Hardin J, Sadelain M, Gage FH (1994) Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 91:4348-4352
4. Blankenstein T, Qin Z, Uberla K, Muller W, Rosen H, Volk HD, Diamantstein T (1991) Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 173:1047-1052
5. Bonnekoh B, Greenhalgh DA, Bundman DS, Eckhardt JN, Longley MA, Chen SH, Woo SLC, Roop DR (1995) Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol 104:313-317
6. Bubenik J, Simova J, Jandlova T (1990) Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett 23:287-292
7. Cai DW, Mukhopadhyay T, Liu Y, Fujiwara T, Roth JA (1993) Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 4:617-624
8. Chen L, Ashe S, Brady NA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by B7 counterreceptor for the T lympocyte molecules CD28 and CTLA-4. Cell 71:1093-1102
9. Chen SH, Shine JD, Goodman JC, Grossman RG, Woo SLC (1994) Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 91:3054-3057
10. Colombo MP, Ferrari G, Stoppacciano A, Parenza M, Rodolfo M, Mavilio F, Rodolfo M, Mavilio F, Parmiani G (1991) Granulocyte colony-stimulating factor gene transfer supresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 173: 889-897
11. Cordier L, Duffour MT, Sabourin JC, Lee MG, Cabannes J, Ragot T, Perricaudet M, Haddada H (1995) Complete recovery of mice from a pre-estblished tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther 2:16-21
12. Cough RB, Chanock RM, Cate TR, Lang DJ, Knight V, Huebner RJ (1963) Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract. Am Rev Resp Dis 88: 394-403
13. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550-1552
14. Descamps V, Blumenfeld N, Perricaudet M, Beuzard Y, Kremer E (1995) Adenoviral-organoids directing systemic expression of erythropoietin in mice. Gene Ther 2:411-417
15. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
16. Faradji A, Bohbot A, Frost H, Scmitt-Gaguel M, Siffert JC, Dufour P, Eber M, Lallot C, Wiesel ML, Bergerat JP, Obering F (1991) Phase I study of liposomal MTP-PE-activated autologous monocytes adminastrated intraperitoneally to patients with peritoneal carcinogenesis. J Clin Oncol 9:1251-1260
17. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403
18. Freeman SM, Abboud CN, WhartenbyKA, Packman CH, Koeplin DS, Moolten FL, Abraham GN (1993) The "bystander effect:" tumor regression when a fraction of tumor mass is genetically modified. Cancer Res 53:5274-5283
19. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990a) Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumoral immunity. Cancer Res 50:7820-7825
20. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilbao E (1990b) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224
21. Gilardi P, Courtney M, Pavirani A, Perricaudet M (1990) Expression of human alpha-1-antitrypsin using a recombinant adenovirus vector. FEBS 267:60-62
22. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713-716
23. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus 5. J Gen Virol 36:59-72
24. Greber UF, Willets M, Webster P, Helenius A (1993) Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75: 477-486
25. Haddada H, Vaux Saint Cyr C (1980) Suppressive and cytostatic activities in the spleen of tumor-bearing hamsters. Eur J Cancer 16:841-848
26. Haddada H, Ragot T, Cordier L, Duffour MT, Perricaudet M (1993a) Adenoviral interleukin-2 gene transfer into P815 tumor abrogates tumorigenicity and induces antitumoral immunity in mice. Hum Gene Ther 4:703-711
27. Haddada H, Lopez M, Martinache C, Ragot T, Abina MA, Perricaudet M (1993b) Efficient adenovirus-mediated gene transfer into human blood monocyte-derived macrophages. Bioch Bioph Res Com 195:1174-1183
28. Haddada H, Ragot T, Cordier L, Duffour MT, Perricaudet M (1993) Adenovirul interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum Gene Ther 4:703-711
29. + T cell-dependent tumor rejection. J Exp Med 174:1291-1298
30. Hui K, Grosveld F, Festenstein H (1984) Rejection of transplantable AKR leukemia cells following MHC DNA-mediated cell transplantation. Nature 311:750-752
31. Jicha DL, Mulé JJ, Rosenberg SA (1991) Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 174:1511-1515
32. Lee MG, Abina MA, Haddada H, Perricaudet M (1995) The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther 3:256-262
33. d by cytolytic T cells. Cell 58:293-303
34. Luster AD, Leder P (1993) IP-10, a C-X-C chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 178:1057-1065
35. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L (1992) The origin and function of tumor-associated macrophages. Immunol Today 13:265-270
36. McBride WH, Thacker JD, Comora S, Economou JS, Kelley D, Hogge D, Dubinett SM, Dougherty GJ (1992) Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res 52:3931-3937
37. Mercer WE, Shields MT, Lin D, Appella E, Ulrich SJ (1991) Growth suppression induced iby wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci USA 88:1958-1962
38. Morgan DA, Ruscetti FW, Gallo RG (1976) Selective in vitro growth of T-lymphocytes from normal bone marrow. Science 193:1007-1008
39. Mule JJ, Mc Intosh JK, Jablons DM, Rosenberg SA (1990) Antitumor activity of recombinant interleukin 6 in mice. J Exp Med 171:629-636
40. Mule JJ, Custer MC, Travis WD, Rosenberg SA (1992) Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 148:2622-2629
41. Pardoll DM (1993) Cancer vaccines. Immunology Today 14: 310-316
42. Porgador A, Tzehoval E, Katz A, Vadal E, Revel M, Feldman M, Eisenbach L (1992) Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52:3679-3686
43. Rollins BJ, Sunday ME (1991) Suppression of tumor formation in vivo by reversion of the JE gene in malignant cells. Mol Cell Biol 11:3125-3131
44. Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180-199
45. Rosenfeld MA, Siegried W, Yoshimura K, Yoneyama K, Fukayama M, Siter LE, Paakko P, Gilardi P, Stratford-Perricaudet LD, Perricaudet M, Pavirani A, Lecocq JP, Crystal RG (1991) Adenovirus-mediated transfer of a recombinant alpha-1-antitrypsin gene to the lung epithelium in vivo. Science 252:431-434
46. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet L, Perricaudet M, Guggino WB, Pavirani A, Lecocq JP, Crystal RG (1992) In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-155
47. Russel SJ, Eccles SA, Flemming CL, Johnson CA, Collins MK (1991) Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 47:244-251
48. Spergel JM, Hsu W, Akira S, Thimmappaya B, Kishimoto T, Chen-Kiang S (1992) NF-IL6, a member of the C/EBP family, regulates E1a responsive promoters in absence of E1a. J Virol 66:1021-1030
49. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P (1992) Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 90:626-630
50. Tahara H, Lotze MT (1995) Antitumoral effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 2:96-106
51. Teng MN, Park BH, Koeppen HK, Tracey KJ, Fendly BM, Schreiber H (1991) Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA 88:3535-3539
52. Tepper RI (1992) The tumor-cytokine transplantation assay and the antitumor activity of interleukin-4. Bone Marrow Transpl 9 [Suppl I]:177-181
53. Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503-512
54. Tominaga O, Hamelin R, Remvikos Y, Salmon RJ, Thomas G (1992) p53 from basic research to clinical applications. Crit Rev Oncog 3:257-282
55. Top FH, Buescher EL, Bancroft WH, Russell PK (1971) Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis 124:155-160
56. + T cells by B7-transfected melanoma cells. Science 259:368-72
57. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van der Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647
58. Vile RG, Hart IR (1993) Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 53:3860-3864
59. Vile RG, Nelson JA, Castlden S, Chong H, Hart IR (1994) Systemic therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54:6228-6234
60. Wallich R, Bulbuc N, Hammerling G, Katzav S, Segal S, Feldman M (1985) Aberration of metastatic properties of tumor cells by de novo expression of H-2 K antigens following H-2 gene transfection. Nature 315:301-305
61. Wang J, Bucana CD, Roth JA, Zhang WW (1995) Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 2:9-17
62. Watanabe B, Kuribayashi K, Miyatake S, Nishihara K, Nakayama EI, Taniyama T, Sakata TA (1989) Exogenous expression of mouse interferon-gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 86:9456-9460
63. Wilson C, Kay MA (1995) Immunomodulation to enhance gene therapy. Nature Med 1:887-889
64. Yang Y, Nunes FA, Berncsi K, Furth EE, Gönczöl E, Wilson JM (1994a) Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407-4411
65. Yang Y, Erth HCJ, Wilson JM (1994b) MHC class 1 restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El deleted recombinant adenoviruses. Immunity 1:433-442
66. Yang Y, Nunes FA, Berncsi K, Furth EE, Gönczöl E, Engelhardt JF, Wilson JM (1994c) Inactivation of E2a in recombinant adenoviruses limits cellular immunity and improves the prospect for gene therapy of cystic fibrosis. Nature Genet 7:363-369
67. Yang Y, Trinchieri G, Wilson JM (1995a) Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1:890-893
68. Yang Y, Xiang Z, Erth HCJ, Wilson JM (1995b) Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 92:7257-7261
69. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA (1994) High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1:5-13